Business context and reporting period
Security Devices International, Inc. (the registrant named in this filing; not Byrna Technologies Inc.) filed this unaudited Form 10-Q for the quarter ended May 31, 2012. The company described itself as a development-stage less-lethal defense technology business developing 40mm blunt-impact (BIP40) and wireless electric (WEP40) projectiles. It reported no revenue since inception.
Financial performance and position
| Metric | Six months ended May 31, 2012, unless noted |
|---|---|
| Revenue | None reported; the company stated it had generated no revenue since inception. |
| Operating expenses | $511,463 net, including $721,920 in general and administrative costs and a $215,143 research and product development cost recovery. |
| Net loss | $600,640; loss per share was $0.02. Three-month net loss was $492,631. |
| Cash from operations | $(807,696); investing cash flow was $(5,079), and financing provided $880,000. |
| Cash and current liquidity | Cash was $182,060 at May 31, 2012. Current assets were $320,524 and current liabilities $294,706, leaving working capital of $25,818. |
| Debt and total liabilities | Convertible debentures had a reported carrying value of $1,713,277, including $146,500 classified as current. Total liabilities were $1,861,483. |
| Stockholders’ deficit | $(1,522,152). Common shares outstanding were 26,828,050 at May 31 and July 16, 2012. |
Profit margins are not meaningful because the filing reports no revenue.
Material changes versus the prior comparable period
- Six-month net loss increased to $600,640 from $492,631. Operating cash use increased to $807,696 from $537,640.
- Financing cash inflow was $880,000, compared with $356,500 in the first six months of 2011; the company reported issuing $880,000 of convertible debentures during the period.
- Accounts payable and accrued liabilities fell to $148,206 from $568,995 at November 30, 2011, following a settlement with former research and development contractor Elad Engineering. The company paid $100,000 to extinguish a reported $315,143 payable and recorded a $215,143 recovery.
- The company granted 905,000 options and issued 800,000 warrants in January 2012; it also exchanged 850,000 previously issued options to Elad principals for warrants. No common shares were issued during the six-month period.
Outlook, risks, contingencies and unusual items
- Management said BIP40 had moved into production, its injection molds were completed, and the product passed a third-party human-effects testing protocol. The filing said final wound profiling and a complete testing report were expected in the third quarter. WEP40 and two additional impact-round concepts remained under development.
- The company estimated $645,000 of capital requirements for the 12 months ending May 31, 2013: $110,000 for development and production and $535,000 for general and administrative expenses. It said it had no committed arrangements for additional capital and could not fund these needs without further financing.
- The filing states that accumulated losses were $17,876,848, the company had no operating cash flows, and it expected further losses. Management said these conditions raised substantial doubt about the company’s ability to continue as a going concern.
- Two debentures totaling $146,500 were past their stated March and April 2012 maturities and had not been converted as of the filing’s reporting date. The filing also describes certain newer debentures as due January 16, 2015 in some places but says “January 16, 2012” elsewhere; the maturity date is unclear in the filing text.
- Related-party consulting and management costs included $126,000 in director management fees and $101,600 for services from a company in which the COO had an interest. The filing also disclosed ongoing consulting and lease commitments.
Important facts for investors to verify
- Confirm the issuer identity and reporting-period details: this filing names Security Devices International, Inc., not Byrna Technologies Inc.
- Confirm debenture maturity dates, repayment status, interest obligations, and potential dilution from conversion features and warrants.
- Assess whether additional financing is available to meet the stated $645,000 capital need and address the going-concern uncertainty.
- Verify the completion and results of the BIP40 testing report, production readiness, and any actual sales or regulatory/customer approvals.
- Review the Elad settlement, related-party arrangements, and the significant noncash stock-based compensation disclosed in the filing.